RGRX (Regenerx Biopharmaceuticals) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2023)


What is Regenerx Biopharmaceuticals ROE % Adjusted to Book Value?

Regenerx Biopharmaceuticals RGRX ROE % Adjusted to Book Value is 0.00% as of Mar. 2023.

Regenerx Biopharmaceuticals's ROE % for the quarter that ended in Mar. 2023 was 0.00%. Regenerx Biopharmaceuticals's PB Ratio for the quarter that ended in Mar. 2023 was N/A. Regenerx Biopharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2023 was N/A.

Regenerx Biopharmaceuticals ROE % Adjusted to Book Value Related Terms

Regenerx Biopharmaceuticals ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Regenerx Biopharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerx Biopharmaceuticals ROE % Adjusted to Book Value Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RGRX vs MYMX, RGMP, NBRVF: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Regenerx Biopharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenerx Biopharmaceuticals ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Regenerx Biopharmaceuticals's ROE % Adjusted to Book Value falls into.


Regenerx Biopharmaceuticals ROE % Adjusted to Book Value Calculation

Regenerx Biopharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Regenerx Biopharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Regenerx Biopharmaceuticals (RGRX) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Regenerx Biopharmaceuticals and its competitors.
Is Regenerx Biopharmaceuticals' ROE % Adjusted to Book Value too high?
Regenerx Biopharmaceuticals' current ROE % Adjusted to Book Value is 0.00%.
How does Regenerx Biopharmaceuticals' ROE % Adjusted to Book Value compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Regenerx Biopharmaceuticals and its competitors. Regenerx Biopharmaceuticals's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerx Biopharmaceuticals Business Description

Address 15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.